Patients with metastatic colorectal cancer can be reassured that their overall quality of life likely won t suffer if they opt for tumor debulking, a new study suggests.
For patients with multiorgan metastatic colorectal cancer (mCRC), adding maximum tumor debulking to systemic therapy is associated with more serious adverse events but no difference in health-related quality of life (HRQoL).
FRIDAY, Oct. 20, 2023 (HealthDay News) For patients with multiorgan metastatic colorectal cancer (mCRC), adding maximum tumor debulking to systemic therapy is associated with more serious adverse events but no difference in health-related quality of life (HRQoL), according to a study in the October issue of the Journal of the National Comprehensive Cancer Network.
FRIDAY, Oct. 20, 2023 (HealthDay News) For patients with multiorgan metastatic colorectal cancer (mCRC), adding maximum tumor debulking to systemic therapy is associated with more serious adverse events but
FRIDAY, Oct. 20, 2023 (HealthDay News) For patients with multiorgan metastatic colorectal cancer (mCRC), adding maximum tumor debulking to systemic therapy is associated with more serious adverse events but